A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, MD MSCE
Associate Professor of Medicine
Director, Clinical Research Unit
Abramson Cancer Center
Perelman School of Medicine
University of Pennsylvania
Steroids
- Dexamethasone
- Prednisone

HDACi
- Panobinostat

Imids
- Thalidomide
- Lenalidomide
- Pomalidomide
  - *iberdomide*

PIs
- Bortezomib
- Carfilzomib
- Ixazomib

MoAbs
- Daratumumab
- Isatuximab
- Elotuzumab

Cytotoxics
- Melphalan
- Cyclophosphamide
- Doxorubicin
- Bendamustine

PIs
- Bortezomib
- Carfilzomib
- Ixazomib

Imids
- Thalidomide
- Lenalidomide
- Pomalidomide
  - *iberdomide*

Steroids
- Dexamethasone
- Prednisone

XPO1i
- Selinexor

BCMA-directed
- Belantamab

CAR T cells
- BiTEs
Myeloma – Treatment and Progression

1. Adapted from International Myeloma Foundation; 2001. Reprinted with permission.
Tasquinimod

- Oral once-daily dosing

- Novel mechanism of action

- Prior evidence of safety and anti-cancer activity in human trials
  - Safety data from more than 650 person-years of exposure
  - Statistically significant PFS benefit in patients with prostate cancer
    Sternberg et al. J Clin Oncol 2016;34:2636-2643
Preclinical Data and Mechanism of Action

- Tasquinimod inhibits S100A9, thereby:
  - Decreasing localized immune suppression in the bone marrow microenvironment
  - Decreasing production of pro-inflammatory cytokines
  - Decreasing production of pro-angiogenic factors

- Reduces tumor growth and improves survival of myeloma-bearing mice

- Synergistic or additive effects in combination with standard myeloma agents
  - Bortezomib (proteasome inhibitor)
  - Lenalidomide (immunomodulatory drug)
Dose Rationale for Phase 1 Trial in Myeloma

- Well tolerated in healthy volunteers
  - At repeat doses up to 1.0 mg but not at 2.0 mg
  - Intermediate doses not studied

- MTD initially determined to be 0.5 mg daily in patients with solid tumors
  - Based on toxicities that are not necessarily dose limiting (tachycardia and elevated amylase)

- Long-term dosing at 1.0 mg daily was feasible in patients with prostate cancer
  - Studies have used a dose up-titration run-in (0.25 mg x2 weeks, 0.5 mg x2 weeks)

- Subsequent studies:
  - Have not evaluated starting at a full dose of 1.0 mg daily
  - Have not evaluated doses between 1.0 and 2.0 mg
Objectives

1. Establish the Maximum Tolerated Dose (MTD) and optimal schedule of single-agent tasquinimod in patients with relapsed or refractory Multiple Myeloma (rrMM)
   ‣ Explore faster up-titration schedules
   ‣ Explore doses between 1.0 and 2.0 mg daily

2. Investigate the MTD of tasquinimod in combination with ixazomib, lenalidomide, and dexamethasone (IRd)

3. Assess preliminarily the efficacy of tasquinimod alone and in combination with IRd

NCT 04405167
Clinical Phase 1 Study

Primary objective:
Tolerability and optimal schedule for TASQ

Secondary objectives:
Safety and preliminary assessment of clinical response

Population:
MM relapsed or refractory after ≥1 line of anti-MM therapy and refractory or intolerant to lenalidomide, pomalidomide, bortezomib, carfilzomib, and an anti-CD38 mAb

Part A1
Tasquinimod dose-escalation (TASQ)

Part B1
Tasquinimod dose-escalation (TASQ + IRd)

Part A2
Cohort expansion at tasquinimod-MTD (TASQ)

Part B2
Cohort expansion at MTD of tasquinimod in combo (TASQ + IRd)

Population:
MM relapsed or refractory after ≥1 line of anti-MM therapy and refractory to most recent PI/IMiD-combination

IRd = Ixazomib + Revlimid® (lenalidomide) + dexamethasone
PI / IMiD = Proteasome Inhibitor / Immunomodulator
TASQ = Tasquinimod

NCT 04405167
Study Design

Open-label, two-part, dose-escalation with subsequent exploratory cohort expansion

Phase-1 Tolerability assessments
- Cohort 1
- Cohort 2 (MTD)
- Cohort 3
- Cohort 4
- Cohort 5
- 3 (+3) total

Phase-2a Safety and response assessments
- 12 total

TASQ + IRD

TASQ

NCT 04405167
Dose Escalation: Single Agent

<table>
<thead>
<tr>
<th>Dose-level</th>
<th>Daily dose of tasquimod (TASQ)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>1.5 mg</td>
</tr>
<tr>
<td>4</td>
<td>1.25 mg</td>
</tr>
<tr>
<td>3</td>
<td>1 mg</td>
</tr>
<tr>
<td>2</td>
<td>0.5 mg x 1 week, then 1 mg</td>
</tr>
<tr>
<td>1</td>
<td>0.25 mg x 1 week, 0.5 mg x 1 week, then 1 mg</td>
</tr>
</tbody>
</table>
Dose Escalation: Drug Combination

<table>
<thead>
<tr>
<th>Dose-level</th>
<th>Daily dose of tasquinimod</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>MTD</td>
</tr>
<tr>
<td>1</td>
<td>One dose-level below MTD*</td>
</tr>
</tbody>
</table>

* - OR - same as dose-level 1 for tasquinimod as single agent, if lower

In 4-week cycles:
- Ixazomib: 4 mg on days 1, 8, and 15
- Lenalidomide: 25 mg on days 1 through 21
- Dexamethasone: 40 mg on days 1, 8, 15, and 22
Assessments

- **T tolerability (Maximum Tolerated Dose, MTD):**
  - Dose-limiting toxicities based on treatment-emergent grade 3/4 Adverse Events (AEs) using the National Cancer Institute (NCI) Common Toxicity Criteria for AEs (CTCAE, version 5)

- **Preliminary anti-myeloma activity:**
  - Overall Response Rate (ORR, partial response or better) based on IMWG response criteria
  - Time-to-event endpoints (Time to progression, Progression-Free Survival, Overall Survival)

- **Biomarkers in bone marrow and plasma for exploratory mechanistic studies:**
  - S100A9 levels in peripheral blood and bone marrow plasma
  - S100A9 expression in peripheral blood and bone marrow cells
  - Frequencies of myeloid derived suppressor cells, dendritic cells, monocytes, and T cells and expression of S100A9 receptors TLR4, RAGE, and CD147
  - Immune suppressive ability of bone marrow myeloid derived suppressor cells
  - Levels of pro-inflammatory and angiogenic factors in plasma samples
  - Number of megakaryocytes and blood vessel density in bone marrow core biopsies.

NCT 04405167
Acknowledgments

This study is supported by:

- Leukemia & Lymphoma Society Translational Research Program Award
- Funding from Active Biotech

- Abramson Cancer Center of the University of Pennsylvania
  - Dan Vogl, MD (Principal Investigator)
  - Clinical Research Team: Harjeet Sembhi (Program Manager), Chau Nguyen (Research Nurse), Rimzim Taneja (Research Coordinator)
  - Biostatistician: E. Paul Wileyto

- Nefedova Laboratory, Wistar Institute
  - Yulia Nefedova, MD PhD

- Sponsor Support Unit, Office of Clinical Research, University of Pennsylvania
- Investigational Drug Service, University of Pennsylvania